IACRN and ACRES Form Global Research Alliance
IACRN and ACRES have created a strategic alliance agreement.
The International Association of Clinical Research Nurses (IACRN) and the Alliance for Clinical Research Excellence and Safety (ACRES) have created a strategic alliance agreement, setting the stage for multiple collaborative projects.
The two organizations will work together to identify the clinical research nurse workforce worldwide, to develop and conduct initiatives focused on evidence-based best practices in clinical research nursing and to co-develop and present at key conferences. Also, ACRES will provide representation and expertise for clinical research nursing in initiatives aimed at establishing research site standards.
“Clinical research obviously has a global reach,” noted Liza Behrens, current President of IACRN, “and while our nurse members bring passion and expertise in enhancing the quality and safety to clinical research through the use of specialty nursing practices, this alliance with ACRES will definitely widen and positively impact clinical research practices throughout the world.”
IACRN’s main aim is to enhance clinical research quality and safety through specialized nursing practice by defining, validating and advancing clinical research nursing as a specialty practice as well as by supporting the professional development of registered nurses who directly or indirectly impact the care of clinical research participants.
On the other hand, ACRES seeks to collaboratively leverage the expertise and investments of research stake-holders world-wide to build and maintain a global system for clinical trials that are conducted according to the highest standards of safety, quality, and efficiency while aligning ethical principles with good business practices to benefit all peoples.
"The education, training, skills, commitment and judgment of all professionals in clinical research are keys to quality and safety, and none of these are more important than the role of professional research nurses. Our strategic relationship with IACRN will ensure that this important perspective is fully represented as ACRES allies work together to build a global system for clinical research that recognizes and rewards excellence worldwide," noted Dr. Honorio Silva, ACRES Vice-President for Professionalism and Systems Integration.
Read the full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
